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Abstract
The complement regulator CD46 is a costimulatory molecule for human T cells that induces a regulatory Tr1 phenotype,
characterized by large amounts of IL-10 secretion. Secretion of IL-10 upon CD46 costimulation is largely impaired in T cells
from patients with multiple sclerosis (MS). Vitamin D can exert a direct effect on T cells, and may be beneficial in several
pathologies, including MS. In this pilot study, we examined whether active vitamin D (1,25(OH)2D3 or calcitriol) could
modulate the CD46 pathway and restore IL-10 production by CD46-costimulated CD4+ T cells from patients with MS. In
healthy T cells, calcitriol profoundly affects the phenotype of CD46-costimulated CD4+ T cells, by increasing the expression
of CD28, CD25, CTLA-4 and Foxp3 while it concomitantly decreased CD46 expression. Similar trends were observed in MS
CD4+ T cells except for CD25 for which a striking opposite effect was observed: while CD25 was normally induced on MS T
cells by CD46 costimulation, addition of calcitriol consistently inhibited its induction. Despite the aberrant effect on CD25
expression, calcitriol increased the IL-10:IFNc ratio, characteristic of the CD46-induced Tr1 phenotype, in both T cells from
healthy donors and patients with MS. Hence, we show that calcitriol affects the CD46 pathway, and that it promotes anti-
inflammatory responses mediated by CD46. Moreover, it might be beneficial for T cell responses in MS.
Citation: Kickler K, Ni Choileain S, Williams A, Richards A, Astier AL (2012) Calcitriol Modulates the CD46 Pathway in T Cells. PLoS ONE 7(10): e48486. doi:10.1371/
journal.pone.0048486
Editor: Pablo Villoslada, Institute Biomedical Research August Pi Sunyer (IDIBAPS) – Hospital Clinic of Barcelona, Spain
Received July 12, 2012; Accepted October 2, 2012; Published October 29, 2012
Copyright:  2012 Kickler et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by a research grant from the MS Society to ALA (859/07). The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: a.astier@ed.ac.uk
Introduction
CD46 is a regulator of complement activity that binds to the
C3b and C4b complement components, allowing their cleavage by
factor I [1]. CD46 also binds to several pathogens [2] and
promotes autophagy upon pathogen binding providing a crucial
step in the control of infections [3]. Moreover, CD46 is key in the
regulation of the adaptive immune response. Costimulation with
CD3/CD46 leads to increased T cell proliferation [4], regulates T
cell mediated inflammation in a CD46-transgenic mouse model
[5], induces morphological changes [6] and affects T cell polarity
[7]. The enzymatic processing of CD46 is involved in the control
of T cell homeostasis, by regulating not only activation but also
termination of T cell responses [8,9]. Importantly, CD46
costimulation promotes Tr1-like Treg differentiation, character-
ized by secretion of large amounts of IL-10 and low levels of IFNc
[10,11]. Defects in IL-10 production upon CD46 activation have
been demonstrated in patients with MS [12,13,14], asthma [15]
and rheumatoid arthritis [11].
Vitamin D deficiency has been associated with a higher rate of
several diseases including MS and asthma [16,17,18]. Active
Vitamin D (1,25(OH)2D3 or calcitriol) has some immunoregula-
tory capacity, with reports of a direct action on T cells [19]. T cell
activation induces the Vitamin D receptor (VDR) [20,21], that is
required for TCR signaling and T cell activation [22]. Calcitriol
can decrease secretion of IFNc [23,24,25], modulates IL-10
production and generates Tregs [26,27,28,29,30,31], which are
essential for immune homeostasis. Treatment with calcitriol
suppresses the development and progression of EAE, the murine
model of MS [29,32,33], and ameliorates several other models of
autoimmune diseases [34]. In MS, Vitamin D supplementation is
safe and has been associated with a modulation of T cell responses
[35,36,37]. Although the role of Vitamin D on the immune system
is intensively studied, no study, as far as we are aware, has
investigated the role of calcitriol on CD46 functions. As CD46
costimulation is key in controlling IL-10 production and this
pathway is defective in pathologies modulated by Vitamin D
supplementation, we investigated whether calcitriol could modu-
late CD46 expression and function of activated T cells. The results
of our pilot study show that calcitriol affects CD46 expression and
strongly modulates T cell responses and the phenotype of CD46-
activated T cells from both healthy donors and patients with MS.
However, a striking difference was that CD46-costimulated MS T
cells, in the presence of calcitriol, expressed much lower levels of
CD25 compared to T cells isolated from healthy donors. Although
MS T cells produce less IL-10 than cells from healthy donors,
addition of calcitriol could restore a normal IL-10:IFNc ratio in
patients with MS. These data provide novel mechanisms of action
of calcitriol that warrant further investigation of this pathway in
the pathologies in which CD46 is dysfunctional.
Methods
Ethics Statement
Ethical approval was obtained from the Lothian Health Board
Ethics Committee.
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Antibodies and reagents used
The following antibodies were used to activate T cells: anti-CD3
(OKT3, 5 mg/ml), anti-CD28 (CD28.2, 5 mg/ml), anti-CD46
(MCI.20.6, 10 mg/ml). Calcitriol was purchased from Sigma-
Aldrich and used at 1027M. Recombinant human IL-2 (Tecin)
was added at 10 U/ml. The antibodies for flow cytometry were as
follows: anti-CD46-FITC (clone MEM-258), anti-CD28-PE (clone
28.2), anti-OX40-FITC (clone Ber-ACT35), anti-PD-1-PE (clone
EH12.2H7), anti-4-1BB/CD137-APC (clone 4B4-1) were pur-
chased from Biolegend; anti-Foxp3-APC (clone PCH101;
ebioscience); anti-CD25-APC (clone M-A251), anti-CTLA-4-PE
(clone BNI3) were purchased from BD Pharmingen. The blocking
anti-IL-10Ra was purchased from R&D.
Cell purification and activation
PBMC were isolated from healthy donors (n = 15) or patients
with MS in the relapsing-remitting stage (n = 11) (see Table 1).
CD4+ T cells were negatively isolated (Miltenyi Biotec, purifica-
tion .90%). In some instances, naı¨ve T cells (Miltenyi) and CD8+
T cells were also purified (EasySep, StemCell, purification .96%)
and studied. T cells (16106 cells/1ml/well) were then activated by
culturing in 24-culture wells pre-coated with anti-CD3, anti-
CD28, or anti-CD46, in RPMI containing 10% FCS [12].
Exogenous IL-2 (10 U/ml) was added to CD3/CD46 costimu-
lated CD4+ T cells as previously described [10]. The active
metabolite of vitamin D3 (1,25-Dihydroxyvitamin D3
(1,25(OH)2D3) or calcitriol) (10
27M) or similar dilutions of 95%
ethanol as vehicle control was added to the culture.
Proliferation assay
Purified T cells (56105 cells/200 ml/well) were cultured in 96-
culture wells pre-coated with anti-CD3 or anti-CD46, in 10%
FCS-RPMI 1640 for 72 hrs, before addition of 0.5 mCi of
[3H]thymidine (Amersham). Proliferation was determined using
a Liquid Scintillation Counter (Wallac).
Suppression assays
Bystander purified T cells were pre-labeled with carboxyfluor-
escein diacetate succinimidyl ester (CFSE) (1 mM; Molecular
Probes Invitrogen) according to manufacturer’s instructions.
Briefly, after 3 washes in cold PBS, T cells (16106/500 ml PBS)
were stained with CFSE for 10 min at 37C, followed by 3 washes
in cold 10% FCS-RPMI 1640 before being added to the wells and
activated by anti-CD3 antibodies in presence of culture medium
or of supernatants of activated T cells. In some experiments,
addition of a blocking anti-IL-10Raantibodies (10 mg) or control
IgG1 was added. After 4 days, cells were harvested and cell
division estimated by flow cytometry.
Flow cytometry
The expression level of CD46, CD28, CD25, Foxp3 and
CTLA-4 on CD4+ and naı¨ve CD4+ T cells was assessed by flow
cytometry. The levels of OX40, 4-1BB/CD137 and PD-1 were
also determined on CD8+ T cells. The relative expression was
calculated by calculating the DMFI (geometric MFI antibody
stained – geometric MFI control antibody), except for Foxp3 for
which the % of Foxp3-expressing cells is represented. Data were
acquired on a FACSCalibur flow cytometer and analyzed with
FlowJoTM software.
Cytokine production
Cytokine production was determined in cell culture super-
natants using ELISA specific for human IL-10 (BD Pharmingen)
and IFNc (Endogen, Thermofisher), as previously reported [12].
Recombinant hIL-10 (BD Pharmingen) and hIFNc (Endogen)
were used as standards. Alternatively, cytokine secretion was also
determined using the IL-10 and IFNc secretion assays from
Miltenyi using anti-IFNc-APC and anti-IL-10-PE detection
reagents, according to the manufacturer’s instructions.
Statistical analyses
The groups using different donors were analyzed using
Graphpad Prism software: data were analyzed using the Wilcoxon
test, a non-parametric test, when comparing paired samples from
the same donors; data were analyzed using the Mann Whitney U-
test when comparing data obtained from patients and healthy
donors. Elisa data obtained from the same experiment were
analyzed using Excel Student’s t-test. All p-values are two-tails and
with a 95% confidence interval. Mean and SEM are represented.
Results
Active Vitamin D (1,25(OH)2D3 or calcitriol) modulates
CD46 expression
We have recently shown that expression of CD46 at the cell
surface of CD4+ T cells is tightly regulated by T cell activation,
and that cleavage of CD46 ectodomain occurred upon its ligation
in activated T cells [8,9]. Hence, we first determined whether
addition of active Vitamin D could affect the expression of cell
surface CD46. CD4+ T cells were purified from blood of healthy
donors and activated with immobilized anti-CD3, anti-CD3/
CD46 or anti-CD3/CD28 antibodies in presence of calcitriol
(1027M, as previously described in [38]) or ethanol as a vehicle
control. Figure 1A shows representative data from one donor after
5 days of culture, and the average results obtained for the different
donors after 2 or 5 days of culture are shown in Figure 1B (n= 15).
As previously reported [9], CD46 expression is strongly down-
regulated upon its own triggering. Addition of calcitriol further
decreased CD46 surface expression (Figure 1A). Calcitriol had not
much effect at day 2, although it slightly increased the levels of
CD46 in unstimulated and CD3-activated T cells (Figure 1B). In
contrast, at day 5, calcitriol significantly decreased CD46 expres-
sion upon CD46 costimulation. This effect was CD46 dependent,
as no significant effect of calcitriol on CD46 expression was
noticed when cells were costimulated by CD28 (Figure 1).
Table 1. Characteristics of the donors used in this study as to
sex, age and disease status.
Healthy controls Patients with MS
Sex 3M/12F 2M/9F
Age (yr, mean6SD) 33.266.02 4168.37
Age range 23–48 27–51
Disease duration (yr, mean6SD) - 1069.3
Disease duration range (yr) - 2–30
EDSS (mean6SD) - 2.6161.94
EDSS median - 2
EDSS range - 0–5.5
Treatment - 7 IFNb/ 3 untreated
doi:10.1371/journal.pone.0048486.t001
Modulation of CD46 Function by Calcitirol
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Calcitriol modulates the phenotype of CD46-activated
CD4+ T cells but differently so in MS T cells
We next compared the effects of calcitriol on the phenotype of
activated CD4+ T cells isolated from the blood of a cohort of
healthy donors (n = 15) or of patients with MS in the relapsing-
remitting stage (RRMS, n= 11). Purified CD4+ T cells were
activated with anti-CD3 or anti-CD3/CD46 antibodies for 5 days
in presence of calcitriol or ethanol, and expression of CD46
(Figure 2A) and of CD28 (Figure 2B), one of the main
costimulatory molecules for T cells, was monitored. Similar effects
of calcitriol on CD46 expression were observed in both cohorts,
with a decrease in CD46 expression observed upon its ligation.
Strikingly, the decrease in CD46 expression observed upon CD46
costimulation was correlated with a strong increase in CD28 levels
(Figure 2C). An increased CD28 expression could also be detected
after 2 days (not shown). A similar increase in CD28 expression
levels was detected in most MS T cells (7 out of 11), but 4 patients
exhibited a lower CD28 expression upon CD46 costimulation in
presence of calcitriol (Figure 2B). Moreover, a slight increase in
CD28 was also detected with calcitriol upon CD3 activation alone
for most healthy T cells but not for MS T cells, suggesting an
abnormal regulation of CD28 expression by calcitriol in some MS
T cells.
We also determined the expression levels of CTLA-4, Foxp3
and CD25, known to be upregulated by CD46 costimulation [9]
and calcitriol [28]. In CD4+ T cells isolated from healthy donors,
addition of calcitriol promoted CTLA-4, Foxp3 and CD25
expression in CD46-activated T cells at day 5 (Figure 3A). The
increase in CTLA-4 and CD25 was correlated to the decrease in
CD46 expression (Figure 3B). A similar increase in CTLA-4 was
detected in MS T cells. Foxp3 expression was only induced on
some donors and lower levels were observed than in healthy T
cells. The most striking effect was observed for CD25. While
CD3/CD46 costimulation was able to induce CD25 expression,
the addition of calcitriol significantly decreased CD25 expression
in all MS T cells except for one donor (Figure 3A). This defect
seems to be specific of CD46 costimulation as not observed upon
CD28 costimulation (Fig. S1). Figure 3C shows representative
data obtained for one healthy control and one patient with MS.
Hence, calcitriol exerts a profound effect on CD46-costimulated
CD4+T cells, by modulating CD46, CD28, CD25, CTLA-4 and
Foxp3 expression, but the modulation of expression of CD25, and
Figure 1. Calcitriol modulates CD46 expression in CD4+ T cells. Purified CD4+ T cells from healthy donors were left unstimulated (US), or
were stimulated by immobilized anti-CD3, anti-CD3/CD28, or anti-CD3/CD46 antibodies as indicated in presence of calcitriol (1027M) or ethanol as
vehicle control. CD46 expression was monitored by flow cytometry. The representative expression of CD46 after 5 days of culture is shown in (A). The
average expression of CD46 detected after 2 or 5 days for the different donors analyzed (mean6 SEM; n = 15) is shown in (B). Samples were analyzed
using the Wilcoxon test.
doi:10.1371/journal.pone.0048486.g001
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in some patients of CD28, is aberrant in MS T cells upon CD46-
costimulation.
Calcitriol promotes the switch from IFNc-producing to IL-
10-secreting cells
We next determined whether addition of active Vitamin D
could modulate CD46 functions first in CD4+ T cells from healthy
donors. CD46 costimulation in presence of IL-2 promotes Tr1
differentiation and allows the cells to switch from producing IFNc
to secreting IL-10 [10,11]. Hence, we assessed the role of calcitriol
on IFNc and IL-10 production. Purified CD4+ T cells were
activated with anti-CD3 or anti-CD3/CD46 antibodies with or
without IL-2, as a control, and in the presence or absence of
calcitriol. After 2 days, production of IL-10 and IFNc was
examined by performing secretion assays (Figure 4A). As expected,
CD3/CD46 costimulation promoted IL-10 secretion compared to
CD3 activation alone, which was particularly boosted by addition
of IL-2. Addition of calcitriol (1027M) strongly increased IL-10
production per cell while it decreased IFNc secretion (Figure 4A).
These data were correlated to the secretion of IL-10 and IFNc
(Figure 4B) in the supernatants determined by ELISA after 4 days.
Although lower levels of cytokine were observed by ELISA (due to
the lower proliferation rate – see Figure 5A), calcitriol had
a stronger effect on IFNc than IL-10, hence resulting in an
increased IL-10:IFNc ratio.
Calcitriol restores a normal IL-10:IFNc ratio in T cells from
patients with MS
A defect in IL-10 production upon CD46 costimulation was first
identified in patients with RRMS [12]. Hence, we next in-
vestigated the effects of calcitriol (1027M) on CD46 function in
a cohort of RRMS patients (n = 10) (Figure 5). Addition of
calcitriol led to lower proliferation of CD46-costimulated T cells in
both cohorts. As expected, CD46-activation induced Tr1 differ-
entiation in CD4+ T cells from healthy donors, visualized by the
increase in the IL-10:IFNc ratio, which was significantly increased
by calcitriol. As previously reported [12], MS T cells secreted less
IL-10 but similar amounts of IFNc after CD46 costimulation
compared to T cells from healthy donors (Figure 5B and C).
Addition of calcitriol had no effect on IL-10 production (while it
decreased IL-10 in T cells from healthy donors) but induced
a dramatic reduction in IFNc secretion, resulting in an increased
IL-10:IFNc ratio, similar to the one observed in healthy donors
(Figure 5D). Hence, these data demonstrate the ability of calcitriol
to restore a correct IL-10:IFNc ratio upon CD46 stimulation in
CD4+ T cells from MS patients.
The supernatants of CD46-costimulated T cells in
presence of calcitriol decrease proliferation of bystander
T cells
As calcitriol promotes secretion of IL-10, an anti-inflammatory
cytokine that reduces T cell proliferation [39], we next assessed
whether the supernatants from calcitriol-treated cells were able to
modulate the activation of bystander T cells. Purified CD4+ T
cells were CFSE-labeled and then activated by anti-CD3 or anti-
CD3/CD28 antibodies in presence of cell culture supernatants
from CD46-costimulated T cells for 5 days in presence or absence
of calcitriol from either one healthy donor or one untreated patient
with RRMS. After 3 days, proliferation was assessed by flow
cytometry (Figure 6A). Proliferation of cells incubated with the
supernatants from calcitriol-treated cells had a lower proliferation
rate than cells cultured with supernatants from cells activated in
absence of calcitriol. Moreover, a decrease in proliferation was also
observed when using supernatants from MS T cells (Figure 6A).
The reduced proliferation was mostly observed upon CD3
activation, the weaker T cell stimulation. Figure 6B shows the
data obtained with the supernatants of CD46-costimulated T cells
in presence or absence of calcitriol from 3 healthy donors.
Calcitriol has a very short half-life and should have been
metabolized after 5 days of culture. Nevertheless, to further
demonstrate that IL-10 was at least partly responsible for the lower
proliferation observed in presence of calcitriol-treated cell super-
natants, we added a blocking anti-IL-10R antibody or control
IgG1 in the assay. Naı¨ve T cells were stimulated with anti-CD3
antibodies at 1 mg/ml, in presence of supernatants from CD46-
Figure 2. Calcitriol promotes concomitant CD46 downregula-
tion and CD28 upregulation in CD46-costimulated CD4+ T
cells. Purified CD4+ T cells from a cohort of RRMS patients (MS) (n = 11)
or healthy controls (HC) (n = 15) were stimulated by immobilized anti-
CD3 or anti-CD3/CD46 antibodies as indicated in presence of calcitriol
(1027M) or ethanol as vehicle control for 5 days. Expression of CD46 (A)
or CD28 (B) was monitored by flow cytometry. Samples were analyzed
using the Wilcoxon test. (C) The dot-plot showing the concomitant
changes in expression of CD46 and CD28 following calcitriol treatment
on CD46-costimulated T cells is represented for one healthy donor.
doi:10.1371/journal.pone.0048486.g002
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cotimulated T cells. Addition of a blocking anti-IL-10R partly
reverted the effects of the supernatants (Figure 6C), suggesting that
IL-10 was at least in part responsible for the lower proliferation of
the bystander T cells.
CD46 costimulation and calcitriol modulates CD8+ T cells
As the role of CD46 activation on human CD8+ T cells has not
been extensively studied, we also examined whether CD46
costimulation affected CD8+ T cells, and whether this was
modulated by the addition of calcitriol. Purified human CD8+ T
cells (Figure S2) were activated by anti-CD3 or costimulated by
anti-CD3/CD46 antibodies in the presence or absence of
calcitriol. We first determined whether CD46 costimulation and
calcitriol could modulate the phenotype of CD8+ activated T cells.
We assessed expression of CD46, CD28, CD25 and Foxp3 but
also of other costimulatory molecules such as 4-1BB (CD137),
OX40 and of the coinhibitory receptors CTLA-4 and PD-1 to
have a broader view of the potential role of CD46 costimulation
on CD8+ T cells (Figure 7 and Figure S2). Similarly to what was
observed in CD4+ T cells, CD46 costimulation led to its
downregulation, which was further increased by addition of
calcitriol. CD46 costimulation also led to increased expression of
CD28, CD25, OX40, 4-1BB, and PD-1 compared to CD3-
activation alone (Figure 7A and Figure S2). In contrast to what
was shown in CD4+ T cells, calcitriol had no effect on CD28 and
CTLA-4 expression (Figure 7A and 7B, respectively), and
decreased CD25, OX40, 4-1BB and PD-1 expression on activated
CD8+ T cells. Calcitriol however slightly increased Foxp3
expression but there was no additional effect of CD46 costimula-
tion. Next, we determined proliferation and production of IFNc
(Figure 7C). CD46 costimulation did not profoundly affect CD8+
T cell responses in this in vitro model, although CD46 costimula-
tion slightly promoted CD8+ T cell proliferation compared to
CD3 activation, and calcitriol decreased the proliferation of both
CD3- and CD3/CD46 activated T cells. Similarly, CD46
costimulation only slightly decreased IFNc production
(Figure 7A), and we were unable to detect any IL-10 in the
supernatants of activated CD8+ T cells (not shown). Calcitriol had
no significant effect on IFNc production. Therefore, CD46
costimulation modulates the phenotype of CD8+ T cells and
calcitriol decreases expression of most of the costimulatory
molecules tested for activated CD8+ T cells.
Figure 3. Calcitriol promotes CTLA-4, Foxp3 and CD25 expression on CD4+ T cells but not in MS. (A) Purified CD4+ T cells from MS
patients or healthy controls (HC) were left unstimulated or stimulated by immobilized anti-CD3 or anti-CD3/CD46 antibodies in presence of calcitriol
(1027M) or ethanol, for 5 days. Expression of CTLA-4, Foxp3 and CD25 was then monitored by flow cytometry. (B) The representative data showing
the concomitant increase in CD25 or CTLA-4 with the downregulation of CD46 upon CD3/CD46 costimulation for one healthy donor are shown. (C)
The representative data showing changes in CD25 expression following addition of calcitriol in one healthy donor and one patient with MS are
shown.
doi:10.1371/journal.pone.0048486.g003
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Discussion
T cell activation is essential to ensure a proper immune
response, and costimulatory molecules are required to exert this
effect. While CD28 has been identified decades ago as a major
costimulatory molecule for T cells, the identification of a role of
CD46 in T cell costimulation is more recent [4] but it is now well
established that CD46 contributes on its own to regulate T cell
activation and differentiation. CD46 can notably promote Tr1
differentiation, and switch T cells from a Th1 to a Tr1 phenotype
depending on the IL-2 present in the milieu, acting therefore as
a sensor for inflammation [10,11]. Moreover, CD46 cell surface
expression on T cells is tightly controlled [9,40]. Its ectodomain is
shed upon CD46 triggering, followed by the processing of its two
cytoplasmic tails. This provides an on/off signal to first activate,
and then deactivate T cells [9]. Hence, CD46 plasticity is crucial
to ensure proper T cell homeostasis, and regulation of its
expression provides a means to control its functions. Importantly,
activated T cells produce some C3b, a ligand for CD46, that may
therefore act as a ligand for autocrine stimulation in vivo [11].
Importantly, the CD46 pathway is altered in an increasing
number of human pathologies. A defect in IL-10 production was
first identified in patients with MS [12,13,14], followed by a report
of defective IL-10 production in patients with asthma [15] and
altered cytokine production was shown in patients with rheuma-
toid arthritis [11]. The fact that CD46 is altered in several
pathologies highlights its importance in controlling T cell
functions. It also underlines the fact that we need to better
understand the molecular mechanisms that regulate its expression.
Vitamin D deficiency has long been correlated with the high
incidence of several human diseases in countries with Northern
latitudes [41]. This notably includes MS, asthma and RA,
pathologies in which the CD46 pathway is defective. Therefore,
Vitamin D supplementation is considered as a potential immuno-
modulatory therapy. Here, we report that the active metabolite of
Vitamin D affects CD46-mediated T cell activation by controlling
CD46 expression and function of both CD4+ and CD8+ T cells.
We show that, after addition of calcitriol, CD46 expression
levels are initially slightly increased in unstimulated CD4+ T cells
and CD3-activated but decreased upon longer activation period
when CD46 is ligated. The increased CD46 expression might
lower the threshold for CD46 activation of cells, resulting in
a higher incidence of IL-10-secreting cells. CD46 ectodomain is
shed by a matrix-metallo-protease (MMP)-dependent cleavage
upon CD46 triggering on T cells [8,9]. It has been shown that
calcitriol upregulates MMP-3 expression in chondrocytes [42], but
downregulates MMP levels in tuberculosis-infected leukocytes
[43]. Hence, modulation of CD46 by calcitriol could be the result
of an indirect effect on MMP levels [9,44,45]. Strikingly, the
decrease in CD46 expression observed upon CD46 costimulation
was correlated with a strong increase in CD28 levels. This effect
was however CD46 dependent, as no effect of calcitriol on CD28
Figure 4. Calcitriol allows the switch from Th1 to Tr1 in CD4+ T cells. (A) Purified CD4+ T cells from one healthy donor were left unstimulated
or stimulated as indicated by immobilized anti-CD3 and anti-CD3/CD46 antibodies, in presence or absence of IL-2 and calcitriol. After 2 days, the
production of IL-10 and IFNc was assessed using the secretion catch assay (Miltenyi). (B) The production of IL-10 and IFNc in the supernatants from
the same wells was also determined by ELISA. The IL-10:IFNc ratio is also represented (mean 6 SEM; samples were analyzed using Student’s t-test).
doi:10.1371/journal.pone.0048486.g004
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expression was noticed when CD4+ T cells were costimulated by
CD3/CD28 (not shown). It has been reported that CD86, one of
the ligands of CD28, is a potential target of calcitriol [46]. Our
data suggest that, by increasing specifically CD28 expression on
CD46-activated T cells, calcitriol participates in a crosstalk
between these two costimulatory molecules, rendering these cells
responsive to further interaction with CD86-expressing APCs.
Moreover, as calcitriol mostly decreases proliferation of CD46-
activated T cells but has a lesser effect on CD3/CD28/CD46
costimulated T cells (data not shown), the increase in CD28
expression might also be a means to prevent lower cell pro-
liferation in the presence of calcitriol. We also show that calcitriol
enhances CD25, Foxp3 and CTLA-4 expression on CD46
costimulated CD4+ T cells isolated from healthy donors. The
increase in CD25 might correlate with the ability of calcitriol to
switch T cells from a Th1 to a Tr1 phenotype in presence of IL-2,
rendering them responsive to IL-2 by upregulation of its receptor.
Importantly, we observed similar trends when calcitriol was added
to purified naı¨ve T cells (Figure S3). Strikingly, in contrast to what
was observed in T cells from healthy donors, and although CD46
costimulation induced CD25 expression in MS T cells, addition of
calcitriol led to a strong decrease in CD25 expression in these cells.
Levels of Foxp3 were lower than in healthy T cells. CTLA-4
expression was not affected, and calcitriol decreased CD46 at the
surface of MS T cells in similar fashion than in healthy T cells.
Importantly, when the same MS T cells were co-activated by
CD3/CD28, CD25 expression was either increased or unaffected
but not decreased, suggesting a specific effect on the CD46
pathway (Figure S1). The regulation of CD28 was normal in most
MS T cells but we observed a decrease in CD28 expression for 4
out of 11 patients. Importantly, in this pilot study, a similar trend
was observed for both IFN beta-treated and untreated patients
although future studies should be performed with larger cohorts. It
is worth noting that polymorphisms in CD25 [47] and in proteins
involved in the vitamin D pathway [48] have been identified in
MS, which might at least partly be relevant to the altered
regulation of CD25 expression in MS. It is also possible that this
mechanism has relevance to the action of vitamin D in MS, as
vitamin D supplementation has been linked to a possible reduction
in disease activity as measured by MRI correlates [49] and early
clinical trials have shown that anti-CD25 immunotherapy shows
promise in reducing the number of MS relapses [50]. Further
investigations should therefore be performed to fully understand
the molecular mechanisms involved in the regulation of CD25
expression by calcitriol in CD46-costimulated T cells.
We also found that calcitriol decreased T cell proliferation of
CD46-costimulated CD4+ T cells as previously reported for CD28
costimulation [51], and so in both healthy donors or RRMS
patients. It is known that calcitriol inhibits proliferation by
inhibiting IL-2 production [21] as the IL-2 gene contains a negative
calcitriol response element (VDRE) in its promoter [52]. However
CD46 activation requires exogenous IL-2, that antagonizes the
effect of calcitriol on proliferation [51]. Moreover, a recent study
has shown that calcitriol affected more the proliferation of
CD4+CD25+Foxp3+ nTreg than conventional responders T cells
[53]. Interestingly, the authors also observed that calcitriol
induced a population of IL-10 secreting T cells. No difference in
proliferation was observed between T cells from healthy donors or
from patients with MS.
In order to provide a broader picture of the effect of calcitriol in
the CD46 pathway in T cells, we also studied CD8+ T cells.
Indeed, CD8+ T cells have been reported to express more CD46
than CD4+ T cells [54]. CD46 costimulation of CD8+ T cells led
to increased proliferation and induced expression of several
markers involved in the regulation of T cell activation (CD28,
CD25, OX40, PD-1). Proliferation of CD8+ T cells was
modulated by calcitriol as previously reported [55], although
calcitriol affected CD8+ less than CD4+ T cells in our in vitro
model. Strikingly, calcitriol had different effects on the phenotype
of CD4+ and CD8+ T cells, as in CD8+ T cells, it decreased
CD25 and had no effect on either CD28 or CTLA-4 expression.
Moreover, addition of calcitriol led to a decreased expression of
most of the costimulatory molecules tested, suggesting that it
lowers CD8+ activation overall. Indeed, CD46 ligation was shown
to reduce CD8+ cytotoxic function in a CD46 transgenic mouse
Figure 5. Calcitriol restores the IL-10:IFNc ratio upon CD46
costimulation of CD4+ T cells in MS. Purified CD4+ T cells from
healthy controls (HC) or RRMS patients (MS) were left unstimulated or
were stimulated as indicated by immobilized antibodies for 4 days, in
presence or absence of calcitriol (1027M). (A) Proliferation was
determined by 3H incorporation. The levels of IL-10 (B) and IFNc (C)
in the supernatants were determined by ELISA (mean 6 SEM; samples
were analyzed using the Wilcoxon test). (D) The IL-10:IFNc ratio is also
represented to bypass the change related to differences in proliferation
(mean 6 SEM; samples were compared using the Mann Whitney U-
test).
doi:10.1371/journal.pone.0048486.g005
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model [5]. Further studies will be necessary to fully elucidate the
role of CD46 on human CD8+ T cell functions.
As already reported, CD46-activation of CD4+ T cells induces
Tr1 differentiation, demonstrated by the increase in the IL-
10:IFNc ratio, which was significantly enhanced by calcitriol. It
was shown that, in presence of IL-2, CD46-activated T cells lower
their IFNc production in favor of IL-10 secretion, switching from
a Th1 toward a Tr1 phenotype [11]. Our data indicate that
calcitriol promotes this switch by not only reducing IFNc
production but also promoting IL-10 secretion upon CD46
costimulation. While, as previously reported, we observed a de-
creased IL-10 production in T cells from MS patients, addition of
calcitriol could restore the overall IL-10:IFNc ratio, by maintain-
ing the IL-10 levels (which are lowered in healthy controls and
correlated with the reduced proliferation observed with calcitriol)
and by promoting a further decrease in IFNc production. These
data suggest that the decrease in CD25 expression observed in MS
T cells upon addition of calcitriol does not impede the beneficial
Figure 6. Calcitriol-treated cell supernatants decrease proliferation of bystander CD4+ T cells. (A) Purified CD4+ T cells were CFSE pre-
labeled and then activated by anti-CD3 or anti-CD3/CD28 antibodies, in presence or absence of culture supernatants from CD46-costimulated T cells
with or without calcitriol from either a healthy donor or a patient with MS, as indicated. Proliferation was assessed by flow cytometry after 3 days. (B)
The data obtained with the supernatants from CD46-costimulated T cells from 3 healthy donors are represented. (C) CFSE-labeled naı¨ve T cells were
activated by anti-CD3 antibodies (1 mg/ml), in presence of cell supernatants from CD46-costimulated T cells with or without calcitriol (n = 3). A
blocking anti-IL-10 antibody or control IgG1 was added to the culture. Proliferation was assessed after 3 days.
doi:10.1371/journal.pone.0048486.g006
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effect of calcitriol on cytokine production, at least in vitro. Calcitriol
has previously been shown to correct defective IL-10 production in
steroid resistant asthma patients [30,31], and in vitro studies have
shown an effect on T cells isolated from patients with Crohn’s
disease [56]. Our data now demonstrate the ability of calcitriol to
affect the CD46 pathway and suggest that it can restore a correct
IL-10:IFNc ratio upon CD46 costimulation in CD4+ T cells from
MS patients. Moreover, the supernatants of CD46-costimulated T
cells in presence of calcitriol further increased their ability to
suppress the proliferation of bystander T cells. Together, these
data further support the role of calcitriol in promoting a regulatory
phenotype upon CD46-activation, expressing higher levels of
regulatory receptors and mainly secreting IL-10. As Vitamin D
appears to be an important factor for several human pathologies, it
will now be crucial to further investigate this pathway not only in
MS but also in patients with other chronic inflammatory diseases.
Supporting Information
Figure S1 Calcitriol promotes CD25 expression upon
CD46 costimulation of CD4+ T cells but not in those
from patients with MS. Purified CD4+ T cells from healthy
controls or RRMS patients were left unstimulated or stimulated by
immobilized anti-CD3, anti-CD3/CD28 or anti-CD3/CD46
antibodies in presence of calcitriol (1027M) or ethanol, for 5 days.
Expression of CD25 was then monitored by flow cytometry.
Representative data showing CD25 expression for one healthy
donor (HC) or 2 MS donors (MS#1 and MS#2) are shown.
(TIF)
Figure S2 CD46 costimulation and calcitriol modulate
the phenotype of CD8+ T cells. CD8+ T cells from 3 healthy
donors (purification shown in (A)) were activated by anti-CD3 or
anti-CD3/CD46 antibodies, in presence or absence of calcitriol.
(B) The levels of CD46, CD28, CD25, OX40, 4-1BB, PD-1,
Figure 7. CD46 costimulation and calcitriol modulate CD8+ T cells. (A) Purified CD8+ T cells from 3 healthy donors were left unstimulated or
stimulated as indicated by immobilized anti-CD3 and anti-CD3/CD46 antibodies, in presence or absence of calcitriol. (A) The expression levels of
surface CD46, CD28, CD25, OX40, PD-1 and 4-1BB were determined by flow cytometry after 3 days. (B) The levels of CTLA-4 and Foxp3 were
determined after intracellular staining. (C) Proliferation was determined by 3H incorporation. The levels of IFNc in the supernatants were determined
by ELISA (mean 6 SEM). The data shown for this donor are representative of the three donors.
doi:10.1371/journal.pone.0048486.g007
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CTLA-4 and Foxp3 was assessed by flow cytometry after 3 days.
The normalized MFIs (to control samples) are shown for the 3
donors, and the samples analyzed using the paired Student’s t-test.
(TIF)
Figure S3 Calcitriol induces similar phenotypic
changes in naı¨ve T cells and CD4+ T cells. Naı¨ve CD4+
T cells (representative purification shown in (A)) were activated by
anti-CD3 or anti-CD3/CD46 antibodies, in presence or absence
of calcitriol for 4 days. (B) The levels of CD28, CD25, CTLA-4
and Foxp3 were then analyzed by flow cytometry and the average
MFI obtained for 3 donors is represented.
(TIF)
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